Drugs comprising combination of antithrombotic agent with pyrazolone derivative
CA 2460141 C · Owner: Yuki, Satoshi · Inventors: Kurita, Katsumi; Yoshii, Narihiko; Tanaka, Tadashi
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
It is intended to provide drugs for treating and/or preventing ischemic diseases which are , safe and have little side effects. Namely drugs comprising a combination of a , tissue plasminogen activator and a pyrazolone derivative of the following formula (I):, (see formula I) , wherein R1 represents hydrogen atom an aryl group, an alkyl group having 1 to 5 carbon atoms , or an alkoxycarbonylalkyl group having 3 to 6 carbon atoms in total; R2 represents hydrogen , atom, an aryloxy group an arylmercapto group, an alkyl group having 1 to 5 carbon atoms or a , hydroxyalkyl group having 1 to 3 carbon atoms; or R1 and R2 is coupled together to form an , alkylene group having 3 to 5 carbon …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 13, 2002 and granted January 10, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 13, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 13, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.